z-logo
open-access-imgOpen Access
Shift From Adalimumab Originator to Biosimilars in Denmark
Author(s) -
Thomas Bo Jensen,
Seoyoung C. Kim,
Espen JimenezSolem,
Dorthe Bartels,
Hanne Rolighed Christensen,
Jón Trærup Andersen
Publication year - 2020
Publication title -
jama internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.14
H-Index - 342
eISSN - 2168-6114
pISSN - 2168-6106
DOI - 10.1001/jamainternmed.2020.0338
Subject(s) - biosimilar , medicine , adalimumab , competition (biology) , market competition , family medicine , pharmacology , rheumatoid arthritis , ecology , economics , market economy , biology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom